EPW
RPRX icon

Evolve Private Wealth’s Royalty Pharma RPRX Stock Holding History

Evolve Private Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Sell
5,164
-3,989
-44% -$208K 0.02% 748
2026
Q1 		$439K Buy
9,153
+1,132
+14% +$49.6K 0.02% 633
2025
Q4 		$310K Buy
+8,021
New +$306K 0.02% 713

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evolve Private Wealth's RPRX Position: Q2 2026 in Review

Evolve Private Wealth reduced its Royalty Pharma (RPRX) stake by 44% in Q2 2026, selling an estimated $208K and leaving 5,164 shares worth $289K. The position accounts for 0.02% of the portfolio, ranked #748.

Evolve Private Wealth first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $439K in Q1 2026. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Evolve Private Wealth held 5,164 shares of Royalty Pharma worth $289K as of Q2 2026.
  • Evolve Private Wealth sold 3,989 Royalty Pharma shares in Q2 2026, an estimated $208K.
  • Royalty Pharma made up 0.02% of Evolve Private Wealth's portfolio in Q2 2026, its #748 holding.
  • Evolve Private Wealth first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • Evolve Private Wealth's Royalty Pharma position peaked at $439K in Q1 2026.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.